Evidence map›Paper›PMID 16498520›Full record

ReviewThe Canadian journal of cardiology2006

PROVE-IT proves that lower is better: a contrary view.

Steven A Grover

Open access · greenAbstract readCommentReview
In one paragraph

Review in The Canadian journal of cardiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Steven A GroverCentre for the Analysis of Cost-Effective Care and the Division of General Internal Medicine, The Montreal General Hospital, Montreal, Quebec. steven.grover@mcgill.ca
Montreal General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiological studies have demonstrated that low density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) are both independent risk factors for future cardiovascular events. Statin therapy, initially developed to modify blood lipid concentrations, has also been shown to have potentially important pleiotropic effects, including a reduction in CRP concentrations. Recent clinical trials have demonstrated conflicting results regarding the benefits associated with intensively lowering LDL cholesterol. An analysis of these results suggests that the different effects of specific statins on CRP concentrations may be an important determinant of the observed overall benefit associated with therapy. These studies together prove that while lowering LDL is beneficial, lowering LDL and CRP is better.

Indexed as

AtherosclerosisCardiovascular DiseasesCholesterol, LDLC-Reactive ProteinHumansHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLC-Reactive ProteinHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID16498520
PMCPMC2780839
OpenAlexW1990858269

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.